What is Bolt Biotherapeutics Price-to-Operating-Cash-Flow?
As of today (2024-04-25), Bolt Biotherapeutics's share price is $1.21.
Bolt Biotherapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.84. Hence, Bolt Biotherapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Bolt Biotherapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
Bolt Biotherapeutics's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.38.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.84.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -7.40% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -9.60% per year.
During the past 6 years, Bolt Biotherapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -2.80% per year. The lowest was -17.90% per year. And the median was -7.40% per year.
Bolt Biotherapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Bolt Biotherapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics Price-to-Operating-Cash-Flow Chart
|
Bolt Biotherapeutics Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
- |
- |
- |
- |
- |
|
Bolt Biotherapeutics Quarterly Data
|
|
Dec18 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Bolt Biotherapeutics's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Bolt Biotherapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's Price-to-Operating-Cash-Flow falls into.
Bolt Biotherapeutics Price-to-Operating-Cash-Flow Calculation
Bolt Biotherapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 1.21 | / | -1.839 |
| = | |
Bolt Biotherapeutics's Share Price of today is $1.21.
Bolt Biotherapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.84.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description
Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Executives
| William P. Quinn |
officer: Chief Financial Officer |
SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
| Edgar Engleman |
director |
575 HIGH STREET, STE 201, PALO ALTO CA 94301 |
| Vivo Capital Fund Viii, L.p. |
10 percent owner |
505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
| Laura Berner |
director |
C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
| Novo Holdings A/s |
10 percent owner |
TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
| James Healy |
director |
3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| Brian O'callaghan |
director |
550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921 |
| Frank D. Lee |
director |
C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472 |
| Kathleen Laporte |
director |
|
| Miller Richard A Md |
director |
PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
| Mahendra Shah |
director |
2250 HOLCOMBE BLVD, HOUSTON TX 77030 |
| Grant Yonehiro |
officer: Chief Business Officer |
C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
| Randall C Schatzman |
director, officer: Chief Executive Officer |
11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
| David Dornan |
officer: Chief Scientific Officer |
C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
| Edith A. Perez |
officer: Chief Medical Officer |
C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063 |
Bolt Biotherapeutics (Bolt Biotherapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOLT has been successfully added to your